Paris, France and Cambridge, Massachusetts, USA, Apr 29, 2017 - (ACN Newswire) - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces its audited consolidated results for the fiscal year ended December 31, 2016:

- Expansion of...